BridgeBio Pharma is a biotechnology business based in the US. BridgeBio Pharma shares (BBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $22.54 – a decrease of 6.51% over the previous week. BridgeBio Pharma employs 550 staff and has a trailing 12-month revenue of around $217.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $22.54 |
|---|---|
| 52-week range | $21.62 - $44.32 |
| 50-day moving average | $25.78 |
| 200-day moving average | $27.63 |
| Wall St. target price | $46.98 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.54 from 2024-11-19
| 1 week (2024-11-14) | -6.51% |
|---|---|
| 1 month (2024-10-21) | -10.41% |
| 3 months (2024-08-21) | -11.82% |
| 6 months (2024-05-21) | -23.02% |
| 1 year (2023-11-21) | -20.38% |
|---|---|
| 2 years (2022-11-21) | 156.43% |
| 3 years (2021-11-19) | 42.65 |
| 5 years (2019-11-21) | 33.54 |
| Revenue TTM | $217.8 million |
|---|---|
| Gross profit TTM | $74.2 million |
| Return on assets TTM | -48.88% |
| Return on equity TTM | -1789.67% |
| Profit margin | -201.53% |
| Book value | $-6.51 |
| Market Capitalization | $4.6 billion |
TTM: trailing 12 months
We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.
Over the last 12 months, BridgeBio Pharma's shares have ranged in value from as little as $21.62 up to $44.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BridgeBio Pharma's is 1.086. This would suggest that BridgeBio Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.